Article Text

PDF
GW24-e2512 A study on plasma PAI-1 and promoter-844 G- A,-675 4G/SG polymorphism of CHD
  1. Chen Yan1,
  2. Zhaoluosha2
  1. 1luoyangshizhongxinyiyuan
  2. 2zhengzhoudaxuediyifushuyiyuan

Abstract

Objectives To investigate the concentration of plasma plasminogen activator inhibitor-1 and the promoter-844G-A substitution,-675 4G/5G polymorphism in patients with CHD and control.

Methods 293 patients with CHD (UAP group andAMIgroup)and 173 human in health (control group )were studied. Plasma PAI-1 antigen was measured by ELISA. The segment of PAI-1 gene was amplified by PCR(-675 4G/5G and-844 G-A). The products of PCR were digested by Xho I(-844 G-A)

Results No difference in genotype frequency was observed in both groups in-844 G-A. There is a difference in genotype frequency was observed between AMI group and the control group in-675 4G/5G, But no difference between UAP and the control in-675 4G/5G. Plasma level of PAI-1 antigen both in UAP and AMI group was higher than that in control group (43.2 ± 22.71 ng/ml, 62.2 ± 24.52 ng/ml, 31.8 ± 25.12 ng/ml, p < 0.01) and related to the 4G/5G and G-A Polymorphism. Carriers of 4G allele have high plasma PAI-1 antigen level.

Conclusions PAI-1 plays an important role in regulation of the fibrinolysis function. In patients with UAP or AMI the PAI-1 antigen was much higher. Promoter-844 G∼A substitution polymorphism have no relationship with the occurrence of UAP and AMI, but-675 4G/5G polymorphism have a relationship with the occurrence of AMI. Carriers of 4G allele have high plasma PAI-1 antigen level.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.